Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Coya Therapeutics, the most common co-covered peer. C-Further appears in 1 tracked Healthcare story from March 15, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 15, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Coya Therapeutics, the most common co-covered peer. C-Further appears in 1 tracked Healthcare story from March 15, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 14 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering C-Further. Shared-story counts are live from our verified record — not editorial picks.
Earnings Release
Expected date for Q4 and full-year 2025 financial results and clinical updates.
MiNK Collaboration
MiNK Therapeutics announces partnership with C-Further for pediatric cancer therapies, stock rises 60%.
Coya Therapeutics and MiNK Therapeutics are scheduled to release quarterly financial results this Tuesday, providing critical updates on their clinical pipelines and cash runways. Investors are closely monitoring MiNK's recent pediatric cancer collaboration and Coya's progress in neurodegenerative Treg therapies.
Source: themarketsdaily.com · themarketsdaily.com
C-Further is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
